For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
How has the acquired immunodeficiency syndrome (aids) grown historically, and what trends indicate future expansion?
The acquired immunodeficiency syndrome (AIDS) market size has grown strongly in recent years. It will grow from $32.09 billion in 2024 to $33.85 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to rising HIV infection rates, increasing government funding for HIV treatment, expansion of global awareness programs, improving diagnostic capabilities, and growing support from non-governmental organizations.
The acquired immunodeficiency syndrome (AIDS) market size is expected to see strong growth in the next few years. It will grow to $41.57 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to growing demand for long-acting injectable therapies, increasing adoption of pre-exposure prophylaxis (PrEP), rising investment in HIV cure research, expansion of telemedicine services for HIV care, a growing focus on personalized medicine, and increasing awareness about early HIV diagnosis. Major trends in the forecast period include a shift towards single-tablet regimens, an increasing preference for injectable and implantable HIV treatments, rising demand for digital health solutions in HIV management, growing interest in functional HIV cure strategies, and the expanding role of artificial intelligence in drug discovery.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp
Which key factors are driving the expansion of the acquired immunodeficiency syndrome (aids) industry?
The increasing rates of HIV infections are expected to propel the growth of the acquired immunodeficiency syndrome (AIDS) market going forward. HIV infections refer to the condition caused by the human immunodeficiency virus (HIV), which attacks the immune system, weakening the body’s ability to fight off infections and diseases. The increasing rates of HIV infections are due to unprotected sexual intercourse with an infected person, sharing needles or syringes, receiving contaminated blood products, having multiple sexual partners, and a weakened immune system or pre-existing sexually transmitted infections. Acquired immunodeficiency syndrome (AIDS) management helps HIV infection patients by promoting early diagnosis, expanding access to effective antiretroviral therapies, enhancing prevention strategies, strengthening healthcare systems that contribute to better control of the virus’s spread. For instance, in November 2024, according to the data published by the European Centre for Disease Prevention and Control (ECDC) Sweden-based European Union agency, a total of 112,883 HIV diagnoses were reported in 2023 across 47 out of 53 countries in the region, with 24,731 cases recorded in the European Union/European Economic Area (EU/EEA). The overall crude rate of HIV diagnoses reached 12.7 per 100,000 population, reflecting a 2.4% increase compared to the 12.4 per 100,000 rates observed in 2022. Therefore, increasing HIV infections is driving the acquired immunodeficiency syndrome (AIDS) market.
How is the acquired immunodeficiency syndrome (aids) market segmented by product, application, and end-user?
The acquired immunodeficiency syndrome (AIDS) market covered in this report is segmented –
1) By Type: Human Immunodeficiency Virus 1, Human Immunodeficiency Virus 2
2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion Inhibitors, CCR5 Anatagonists And Post-Attachment Inhibitors, Protease Inhibitors, Integrase Inhibitors, Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis
3) By Route Of Administration: Oral, Parenteral
4) By Application: Hospital Pharmacy, Retail Pharmacy, Other Applications
5) By Distribution Channel: Offline, Online
Subsegments:
1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), HIV-1 Diagnostic Tests, HIV-1 Vaccine Development, HIV-1 Opportunistic Infection Management
2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2, HIV-2 Diagnostic Tests, HIV-2 Surveillance And Epidemiology, HIV-2 Vaccine Research, Management Of HIV-2 Co-Infections
View The Full Market Report:
Which major trends are influencing the growth of the acquired immunodeficiency syndrome (aids) industry?
Major companies operating in the acquired immunodeficiency syndrome (AIDS) market are focusing on developing innovative therapies such as long-acting injectables, which offer improved patient compliance, reduce the frequency of dosing, and provide a more convenient alternative to daily oral antiretroviral treatments. Long-acting injectables are medications administered via injection that are designed to release their active ingredients slowly over an extended period, allowing for less frequent dosing compared to traditional oral medications. For instance, in January 2025, GSK plc., a UK-based pharmaceutical company, announced the approval from the European Commission for long-acting injectable treatment, Vocabria (cabotegravir) plus Rekambys (rilpivirine). It is approved for use in adolescents aged 12 years and older who are living with HIV. This is administered via intramuscular injection, typically every one or two months, depending on the specific treatment plan. The long-acting nature of the injections may improve adherence rates among adolescents who struggle with daily pill regimens.
Which leading companies are dominating the acquired immunodeficiency syndrome (aids) market landscape?
Major companies operating in the acquired immunodeficiency syndrome (AIDS) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy’s Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare
Which geographic areas are expected to offer the highest growth opportunities in theacquired immunodeficiency syndrome (aids) market?
North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (AIDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Acquired Immunodeficiency Syndrome (AIDS) Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21076
Need Customized Data On Acquired Immunodeficiency Syndrome (AIDS) Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=21076&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
